EQ101 is a first-in-class, tri-specific inhibitor of IL-2, IL-9 and IL-15, three
inflammatory cytokines implicated in multiple diseases. It selectively
blocks those three key pathogenic cytokines while preserving non-
pathogenic signaling related to IL-4, IL-7 and IL-21 and has demonstrated
clinical proof-of-concept as a novel cytokine inhibitor through a completed
Phase 1/2 study in cutaneous T cell lymphoma (CTCL), a dermato-oncology
indication. EQ101 achieved its primary objective of safety and tolerability
and showing clinically meaningful improvements in SWAT scores
(modified severity-weighted assessment tool).
EQ101 was also shown to be well tolerated with a favorable safety profile
with no drug-related SAEs and no dose-limiting toxicities. It is now Phase 2
ready in alopecia areata, a dermatological autoimmune disorder, and is
Phase 2/3 ready in CTCL with open U.S. INDs for each indication, with an
orphan designation for CTCL in the U.S. and Europe. EQ101 is currently
formulated for intravenous administration, with subcutaneous
formulation development underway. Equillium is planning to initially focus
development of EQ101 in patients suffering from alopecia areata, where
there are currently no drugs approved.